Literature DB >> 23566620

[Type 2 diabetes in France: epidemiology, trends of medical care, social and economic burden].

Céline Druet1, Isabelle Bourdel-Marchasson, Alain Weill, Eveline Eschwege, Alfred Penfornis, Sandrine Fosse, Cécile Fournier, Michèle Chantry, Claude Attali, Pierre Lecomte, Dominique Simon, Nathalie Poutignat, Arnaud Gautier, Mathilde Risse, Anne Fagot-Campagna.   

Abstract

Between 2001 and 2007, treatments for type 2 diabetes have increased and therapeutic choices have improved. However glycemic control remains insufficient. Cardiovascular risk control has widely increased. Statins, hypertensive and antithrombotic treatments are more often prescribed. Blood pressure and LDL cholesterol levels have decreased whatever age. However, progress remains possible, especially regarding blood pressure control. Obesity has increased between 2001 and 2007 to reach 41% whereas the frequency of dietetic visits has decreased. Insulin therapy (more than obesity) determines the frequency of dietetic visits: dietetic care happens too late. Important improvements of the quality of follow-up are observed. However, fundus exams and more specifically albuminuria measurement remain insufficiently performed and their progression is too slow, as well as the podiatric examination. Only 10% of people with type 2 diabetes have an endocrinology visit, which has been stable between 2001 and 2007. Information expectations of people with type 2 diabetes are strong, especially for diet. Education demand is lower but more important for people who have already benefited. This improvement of medical care leads to an increase in the cost of reimbursements. The consequences of diabetes, more than the disease itself, alter the quality of life.
Copyright © 2013 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23566620     DOI: 10.1016/j.lpm.2013.02.312

Source DB:  PubMed          Journal:  Presse Med        ISSN: 0755-4982            Impact factor:   1.228


  7 in total

1.  How are patients with type 2 diabetes and renal disease monitored and managed? Insights from the observational OREDIA study.

Authors:  Alfred Penfornis; Jean Frédéric Blicklé; Béatrice Fiquet; Stéphane Quéré; Sylvie Dejager
Journal:  Vasc Health Risk Manag       Date:  2014-06-13

2.  The Use of Saxagliptin in People with Type 2 Diabetes in France: The Diapazon Epidemiological Study.

Authors:  Beverley Balkau; Bernard Charbonnel; Alfred Penfornis; Nora Chraibi; Amir Lahouegue; Céline Faure; Florence Thomas-Delecourt; Bruno Detournay
Journal:  Diabetes Ther       Date:  2017-09-25       Impact factor: 2.945

3.  Less amputations for diabetic foot ulcer from 2008 to 2014, hospital management improved but substantial progress is still possible: A French nationwide study.

Authors:  Coralie Amadou; Pierre Denis; Kristel Cosker; Anne Fagot-Campagna
Journal:  PLoS One       Date:  2020-11-30       Impact factor: 3.240

4.  Use of Vildagliptin in Management of Type 2 Diabetes: Effectiveness, Treatment Persistence and Safety from the 2-Year Real-Life VILDA Study.

Authors:  Dominique Simon; Bruno Detournay; Evelyne Eschwege; Stephane Bouée; Jacques Bringer; Claude Attali; Sylvie Dejager
Journal:  Diabetes Ther       Date:  2014-04-12       Impact factor: 2.945

5.  Inactive matrix gla protein plasma levels are associated with peripheral neuropathy in Type 2 diabetes.

Authors:  Anne-Caroline Jeannin; Joe-Elie Salem; Ziad Massy; Carole Elodie Aubert; Cees Vemeer; Chloé Amouyal; Franck Phan; Marine Halbron; Christian Funck-Brentano; Agnès Hartemann; Olivier Bourron
Journal:  PLoS One       Date:  2020-02-24       Impact factor: 3.240

6.  Costs and its drivers for diabetes mellitus type 2 patients in France and Germany: a systematic review of economic studies.

Authors:  Constance Stegbauer; Camilla Falivena; Ariadna Moreno; Anna Hentschel; Magda Rosenmöller; Tim Heise; Joachim Szecsenyi; Freimut Schliess
Journal:  BMC Health Serv Res       Date:  2020-11-16       Impact factor: 2.655

7.  Relationship between obesity and severe COVID-19 outcomes in patients with type 2 diabetes: Results from the CORONADO study.

Authors:  Sarra Smati; Blandine Tramunt; Matthieu Wargny; Cyrielle Caussy; Bénédicte Gaborit; Camille Vatier; Bruno Vergès; Deborah Ancelle; Coralie Amadou; Leila A Bachir; Olivier Bourron; Christine Coffin-Boutreux; Sara Barraud; Anne Dorange; Bénédicte Fremy; Jean-François Gautier; Natacha Germain; Etienne Larger; Stéphanie Laugier-Robiolle; Laurent Meyer; Arnaud Monier; Isabelle Moura; Louis Potier; Nadia Sabbah; Dominique Seret-Bégué; Patrice Winiszewski; Matthieu Pichelin; Pierre-Jean Saulnier; Samy Hadjadj; Bertrand Cariou; Pierre Gourdy
Journal:  Diabetes Obes Metab       Date:  2020-11-06       Impact factor: 6.408

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.